Snapshot from Jun 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Akeso presents oncology data at ASCO
Tech clinical trial results

Akeso presents oncology data at ASCO

Analysis based on 6 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
70
Attention
6
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive clinical trial results for Akeso's oncology portfolio, particularly for Ivonescimab>>> and Cadonilimab>>>, are expected to significantly boost investor confidence in Akeso>>>. This could lead to an increase in Akeso>>>'s stock price and enhance its competitive position in the biopharmaceutical market, especially within oncology.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Akeso, Inc. announced that over 40 clinical studies from its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. Key highlights include the Phase III overall survival results for Ivonescimab>>> in advanced squamous non-small cell lung cancer from the HARMONi-6 study, which was selected for a prestigious Plenary Session. Additional presentations feature Ivonescimab>>> in small-cell lung cancer and metastatic colorectal cancer, as well as Cadonilimab>>>-based regimens across various tumor types including renal cell carcinoma, melanoma, and head and neck cancer. The company will also present data on Ligufalimab>>>, a novel CD47 monoclonal antibody. These presentations underscore the success of Akeso's bispecific antibody platform and its potential to deliver practice-changing datasets to the international oncology community.

Key Actions
100 Akeso presented Phase III results Ivonescimab
95 Akeso announced presentations American Society of Clinical Oncology
85 Akeso presented clinical data Cadonilimab
70 Akeso presented data Ligufalimab
Entities Involved
stock
Akeso
Akeso is the biopharmaceutical company presenting over 40 clinical studies of its oncology portfolio at ASCO 2026, highlighting the success of its innovation engine and differentiated bispecific antibody platform. The positive clinical trial results, especially for ivonescimab and cadonilimab, are expected to enhance its market position and potential for commercial success.
Importance 100 Sentiment 75
oth
Ivonescimab
Ivonescimab is a core first-in-class bispecific antibody developed by Akeso, with Phase III overall survival results from the HARMONi-6 study being a pivotal highlight at ASCO 2026. Its positive data in various cancers could lead to significant market impact.
Importance 90 Sentiment 70
oth
Cadonilimab
Cadonilimab is another core first-in-class bispecific antibody from Akeso's portfolio, with regimens being presented for various tumor types at ASCO 2026, indicating its potential clinical benefits.
Importance 80 Sentiment 65
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology is hosting its Annual Meeting where Akeso will present its clinical study results, providing a platform for the dissemination of important oncology research.
Importance 60 Sentiment 0
oth
Ligufalimab
Ligufalimab is a novel therapeutic antibody from Akeso, a next-generation CD47 monoclonal antibody, also featured in presentations at ASCO 2026.
Importance 50 Sentiment 60
per
Shun Lu
Professor Shun Lu from Shanghai Chest Hospital is the presenter for the Plenary Session on ivonescimab's HARMONi-6 study results.
Importance 40 Sentiment 0
per
Yun Fan
Professor Yun Fan from Zhejiang Cancer Hospital is presenting on the efficacy and safety of ivonescimab in small-cell lung cancer.
Importance 30 Sentiment 0
per
Junru Chen
Dr. Junru Chen from West China Hospital, Sichuan University, is presenting on a Phase Ib/II trial of cadonilimab plus axitinib in renal cell carcinoma.
Importance 30 Sentiment 0
per
Kunyu Yang
Professor Kunyu Yang from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, is presenting on neoadjuvant ivonescimab in head and neck squamous cell carcinoma.
Importance 30 Sentiment 0
per
Lili Mao
Professor Lili Mao from Peking University Cancer Hospital is presenting on cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma.
Importance 30 Sentiment 0
per
David Berz
David Berz, MD, PhD, from Valkyrie Clinical Trials, Inc, is the first author for an international multicenter Phase II study of ivonescimab in metastatic colorectal cancer.
Importance 30 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.